Skip to main content

Table 2 Time table

From: Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel

Time period Therapy
12.2015 Pat. presented with liver and brain metastases.
12.2015–03.2016 Gemcitabine mono 1000 mg/qm d1–8 15 and selective internal radiotherapy (SIRT) analogous to the SIRCCA study protocol.Excision of the tumor in the ileum and one brain metastasis (02.2016)
05.2016–09.2016 Capecitabine 500 mg (2–0-2, 5d/week)
12.09.16 1. Cycle: Olaparib (200 mg capsules twice daily, administered orally on days 1–10 of each 21-day cycle) plus paclitaxel (175 mg/m2, administered intravenously on day 1) and carboplatin (4 mg/mL per min)
04.10.2016 2. Cycle: Olaparib (200 mg capsules twice daily, administered orally on days 1–10 of each 21-day cycle) plus paclitaxel (175 mg/m2, administered intravenously on day 1) and carboplatin (4 mg/mL per min)
31.10.2016 3. Cycle: Olaparib (100 mg capsules twice daily (reduced dosage), administered orally on days 1–10 of each 21-day cycle) plus paclitaxel (175 mg/m2, administered intravenously on day 1) and carboplatin (4 mg/mL per min)
05.12.2016 4. Cycle: Olaparib (100 mg capsules twice daily (reduced dosage), administered orally on days 1–10 of each 21-day cycle) plus paclitaxel (175 mg/m2, administered intravenously on day 1) and carboplatin (4 mg/mL per min)
09.01.2017 5. Cycle: Olaparib (100 mg capsules twice daily (reduced dosage), administered orally on days 1–10 of each 21-day cycle) plus paclitaxel (175 mg/m2, administered intravenously on day 1) and carboplatin (4 mg/mL per min)
02.2017 liver metastases could be removed
12.2017 Last CT-scan staging: still no further tumor manifestations/still no metastasis